Peptide News Digest

#6-Percent-Decline

2 stories

Industry · View digest

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 6% Thursday August 13, 2026 on Broker Downgrade Citing Continued Franchise-Gap Pressure From Eli Lilly's (NYSE: LLY) Tirzepatide Franchise and the CagriSema Head-to-Head Miss Against Tirzepatide (23.0% Versus 25.5% Weight Loss at 84 Weeks in the REDEFINE 4 Head-to-Head Phase 3 Trial); The August 4 H1 2026 Earnings Release Raised Full-Year 2026 Sales Guidance to Down 3% From Prior Down 8% Midpoint but the Broader Investor Narrative Continues to Focus on Novo's Ability to Defend GLP-1 Franchise Economics Against Eli Lilly's Q2 2026 $23 Billion Revenue Blowout (+48% YoY), Foundayo (Orforglipron) $98 Million First Commercial Quarter, and Retatrutide's 28.7% Phase 3 TRIUMPH-4 Weight Loss Result

Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.

Industry · View digest

Hims & Hers Health (NYSE: HIMS) Shares Fell Approximately 6% After Hours Monday and Extended the Decline Into Tuesday August 11 Trading Despite Q2 2026 Revenue of $753.2 Million (+38% YoY, Beating $698.9M Consensus) and Q3 Guidance of $890 Million (+12.4% Above Consensus); GAAP Loss of $0.37 per Share Was Well Below Analyst Estimates, and Gross Margin Compression to 64% (From 76% Year-Ago) Hit Its Fourth Consecutive Quarter of Decline as the Compounded-to-Branded GLP-1 Pivot Continued to Drag Unit Economics; Q2 Net Loss of $86.3 Million Versus $42.5 Million Net Income in Q2 2025

Hims & Hers Health (NYSE: HIMS) shares fell approximately 6% after hours Monday and extended the decline into Tuesday August 11, 2026 trading despite Q2 2026 revenue of $753.2 million (+38% year-over-year, beating $698.9 million consensus) and Q3 guidance of $890 million at the midpoint (+12.4% above analyst expectations). The GAAP loss of $0.37 per share ran well below analyst estimates, and gross margin compression to 64% (from 76% year-ago) hit its fourth consecutive quarter of decline. Q2 net loss reached $86.3 million versus $42.5 million net income in Q2 2025. The compounded-to-branded GLP-1 pivot through the Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026 continues to drag unit economics. Full-year 2026 guidance was raised to $3.1-3.3 billion revenue and $275-325 million Adjusted EBITDA. The market appears to be pricing the compounded-to-branded pivot as a durable margin drag rather than a transitory transition; the July 29 FTC lawsuit alleging consumer health data sharing with Meta and Snap plus unauthorized billing charges remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the peptide-strategy narrative for the stock.